TY - JOUR AB - Following the publication of this article, an interested reader drew to the authors' attention that, in Fig. 1F on p. 2311 showing a representative high‑grade glioma specimen, the data were either duplicated or overlapping with the data featured in Fig. 1D, which showed a low‑grade glioma specimen. After having consulted their original data, the authors have realized that the data for Fig. 1D were inadvertently selected incorrectly.
The corrected version of Fig. 1, now showing the correct data for the high‑magnification high‑grade glioma specimen in Fig. 1F, is shown on the next page. The authors sincerely apologize for the error that was introduced during the preparation of this figure, thank the Editor of Oncology Reports for granting them the opportunity to publish a Corrigendum, and are grateful to the reader for alerting them to this issue. The authors also regret any inconvenience that this mistake may have caused. [Oncology Reports 42: 2309-2322, 2019; DOI: 10.3892/or.2019.7343] AD - Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China AU - Qi,Yangzhi AU - Deng,Gang AU - Xu,Pengfei AU - Zhang,Huikai AU - Yuan,Fanen AU - Geng,Rongxin AU - Jiang,Hongxiang AU - Liu,Baohui AU - Chen,Qianxue DA - 2023/02/01 DO - 10.3892/or.2022.8473 IS - 2 JO - Oncol Rep KW - immune checkpoint molecule HHLA2 glioma TAMs immunotherapy angiogenesis PY - 2023 SN - 1021-335X 1791-2431 SP - 36 ST - [Corrigendum] HHLA2 is a novel prognostic predictor and potential therapeutic target in malignant glioma T2 - Oncology Reports TI - [Corrigendum] HHLA2 is a novel prognostic predictor and potential therapeutic target in malignant glioma UR - https://doi.org/10.3892/or.2022.8473 VL - 49 ER -